Table 3 Characteristics of participants at study entry, with or without contrast-induced nephropathy (CIN)

Age (years)

54 (4.90)

50.80 (2.12)

0.55

Male gender, n (%)

17 (80.95)

79 (76.69)

0.78

Weight (Kg)

73.23 (2.32)

68.15 (1.34)

0.68

Height (cm)

164

169

0.57

BMI (Kg/m²)

27

26

0.80

APACHE II score

14.95 (1.79)

13.68 (0.69)

0.51

SOFA score

6.53 (0.8)

5.69 (0.34)

0.34

 Medical, n (%)

9 (42.86)

44 (42.72)

0.15

 Surgical, n (%)

2 (9.52)

27 (26.21)

0.15

 Neurosurgical, n (%)

10 (47.62)

32 (31.07)

0.20

 Diabetes, n (%)

2 (9.52)

10 (9.71)

0.68

 Hypertension, n (%)

4 (19.05)

32 (31.07)

0.57

 Cardiovascular, n (%)

3 (14.29)

11 (10.68)

0.70

 Cirrhosis, n (%)

1 (4.76)

0

0.16

 Renal disease, n (%)

1 (4.76)

6 (5.83)

0.41

 Sepsis, n (%)

8 (38.10)

35 (33.98)

0.80

 COPD, n (%)

3 (14.28)

16(15.53)

1.00

 Charlson index score

2.32 (0.57)

2.10 (0.24)

0.70

Serum creatinine (mg/dl)

0.87 (0.08)

0.96 (0,07)

0.39

Serum cystatin-C (mg/L)

1.34 (0.23)

0.98 (0.05)

0.14

Serum urea (mg/dl, median)

55 (8.34)

44 (3.82)

0.18

Serum urea/creatinine

73.19 (6.3)

58.65 (2.5)

0.01

Fluid balance/24 h (ml)

1462 (169)

1058 (338.1)

0.30

Vasoactive therapy, n (%)

9 (42.86)

45 (43.69)

0.13

Noradrenaline dose, γ

0.1 (0.05)

0.06 (0.01)

0.20

Mechanical ventilation, n (%)

15 (71.43)

51 (49.51)

0.09

Diuretic therapy, n (%)

1 (4.76)

19 (18.45)

0.19

ACEi or ARBs, n (%)

7 (33.33)

20 (19.42)

0.19

Nephrotoxic medications, n (%)

19 (90.48)

68 (66.02)

0.03

Volume of contrast agent (ml)

126.3 (5.88)

122.2 (2.77)

0.53

Multiple studies, n (%)

6 (28.57)

13 (12.62)

0.09

Length of ICU stay (days, median)

29 (3.97)

25 (7.85)

0.80

Length of ICU stay before entering the study (days)

20.71 (4.4)

18.15 (2.7)

0.68

ICU mortality, n (%)

6 (28.57)

20 (19.42)

0.38

RRT 10 days post contrast agent, n (%)

3 (14.28)

4 (4.85)

0.09

Total duration on RRT (h)

47.67 (17.32)

49.25 (9.29)

0.93